⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNYSE

PFE

Pfizer Inc.

Healthcare · Drug Manufacturers - General

27.78USD

-0.0100 (-0.04%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$0.76▼$0.85114
Next quarter$0.71▲$0.69114
Current year$2.98▲$2.96154
Next year$2.9▲$2.84154

Recent quarters

Beat in 4 of the last 4

QuarterEstimateActualSurprise
2026-06-30$0.68$0.77+0.09 (+12.9%)
2026-03-31$0.72$0.75+0.03 (+3.9%)
2025-12-31$0.57$0.66+0.09 (+16.2%)
2025-09-30$0.63$0.87+0.24 (+37.4%)

Wall Street coverage

301 ratings from 39 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
GuggenheimMaintainedBuy$35 $31Aug 7, 2026
BMO CapitalMaintainedOutperform$34 $30Jul 13, 2026
GuggenheimMaintainedBuy$36 $35Jul 13, 2026
B of A SecuritiesMaintainedNeutral$27 $26Jul 10, 2026
JP MorganMaintainedNeutral$30 $28Jul 8, 2026
Cantor FitzgeraldReiteratedNeutral$27Jul 6, 2026
HSBCDowngraded from BuyHold$32 $28Jul 6, 2026
RBC CapitalUpgraded from UnderperformSector Perform$25Jun 10, 2026
CitigroupMaintainedNeutral$26 $27Apr 29, 2026
RBC CapitalReiteratedUnderperform$25Apr 20, 2026
CICCInitiatedOutperform$33Apr 16, 2026
UBSMaintainedNeutral$25 $27Apr 13, 2026
Morgan StanleyMaintainedEqual-Weight$27 $28Apr 10, 2026
B of A SecuritiesMaintainedNeutral$27 $26Apr 9, 2026
GuggenheimMaintainedBuy$35 $36Mar 24, 2026
HSBCMaintainedBuy$29 $32Mar 17, 2026
Argus ResearchUpgraded from HoldBuy$35Mar 2, 2026
RBC CapitalInitiatedUnderperform$25Feb 25, 2026
BarclaysInitiatedUnderweight$25Feb 20, 2026
Freedom BrokerMaintainedBuy$35 $33Feb 9, 2026
Cantor FitzgeraldReiteratedNeutral$27Feb 4, 2026
Cantor FitzgeraldMaintainedNeutral$24 $27Jan 27, 2026
Morgan StanleyMaintainedEqual-Weight$28 $27Dec 17, 2025
B of A SecuritiesMaintainedNeutral$29 $28Dec 15, 2025
Morgan StanleyMaintainedEqual-Weight$32 $28Dec 12, 2025

Insider transactions

34 filings from 11 insiders · 3 buy / 2 sell over 6m

Officers and directors of PFE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
BOURLA ALBERTDirector; Officer, Chairman & CEOGrantPhantom Stock Units SSP21$28.46$598Aug 31, 2026
BOURLA ALBERTChief Executive OfficerBuy38.0k$26.34$1.00MAug 12, 2026
BLAYLOCK RONALD EDirectorBuy39.2k$25.46$999kAug 5, 2026
BUCKLEY MORTIMER J.DirectorBuy37.6k$25.52$960kAug 5, 2026
DAMICO JENNIFER B.OfficerSell3.3k$25.40$83kAug 5, 2026
DAMICO JENNIFER B.OfficerSell2.0k$25.70$51kJun 9, 2026
DAMICO JENNIFER B.OfficerGrant21.7k——Mar 3, 2026
BOSHOFF CHRISTOFFELOfficerGrant13.4k——Feb 25, 2026
SAHNI PAYALOfficerExercise56.9k$33.82$1.92MFeb 25, 2026
MCDERMOTT MICHAELOfficerExercise37.9k$33.82$1.28MFeb 25, 2026
DAMICO JENNIFER B.OfficerExercise17.6k$33.82$594kFeb 25, 2026
BOURLA ALBERTChief Executive OfficerExercise491.6k$33.82$16.63MFeb 25, 2026
LANKLER DOUGLAS MOfficerExercise122.9k$33.82$4.16MFeb 25, 2026
FONSECA LIDIA PH.D.OfficerExercise56.9k$33.82$1.92MFeb 25, 2026
DAMICO JENNIFER B.OfficerGrant5.6k——Mar 4, 2025
DAMICO JENNIFER B.OfficerSell2.5k$25.93$65kMar 4, 2025
BOSHOFF CHRISTOFFELOfficerGrant17.4k——Feb 27, 2025
MCDERMOTT MICHAELOfficerExercise48.4k$31.31$1.52MFeb 27, 2025
DAMICO JENNIFER B.OfficerExercise22.4k$31.31$702kFeb 27, 2025
SAHNI PAYALOfficerExercise19.1k$31.31$597kFeb 27, 2025

Analyst Notes

Sign in to write

No analyst notes on PFE yet.

Analyst Ratings

26 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current281611Hold2.68
1 mo ago281611Hold2.68
2 mo ago281611Hold2.68
3 mo ago291611Hold2.66
Price target$28.61$25.00 – $35.75
+3.0% to target